# How AbbVie (ABBV) compares with the whole market and its popular alternatives

> Source: EasyCompare research, https://easycompare.io/research/abbv
> Data as of October 20, 2026. Total returns include reinvested dividends. Past performance does not predict future results; nothing here is investment advice.

Built by QuantCommons' quantitative engine, this page is about relative opportunity, not data on ABBV alone. It places ABBV (AbbVie Inc.) against 20+ popular alternatives, its neighboring categories and the entire market of over 10,000 U.S.-listed stocks and ETFs, and surfaces what has done better on consistent outperformance, return for the risk taken, behavior in real market crashes and diversification. The result is a clearer view of where ABBV stands in the market, and of the alternatives worth a closer look.

Period covered: ABBV's full trading record, from December 2012 through September 2026. The crash tests reach back to 2000 using older funds and the S&P 500. All returns include reinvested dividends. Data as of October 20, 2026.

## Key findings

- **Right now:** Over the past 6 months, ABBV rose 43.8% against 9.1% for the S&P 500 and 11.2% for the Nasdaq 100. ABBV has bounced back 26.2% from its April 2025 low after a 20.7% loss from March 2025 to April 2025 after falling while the S&P 500 fell 8.1%.
- **Stock or market?:** More than an industry move: ABBV rose 14.8% over the past 3 months, against 5.0% for the pharmaceuticals ETF IHE (iShares U.S. Pharmaceuticals ETF). The S&P 500 rose 3.9%. Last month cut against the tape: ABBV rose 9.9% while the S&P 500 fell 0.6%.
- **Past 1 to 3 years:** Over the past year, ABBV rose 28.3% against 15.8% for the S&P 500 and 17.9% for the Nasdaq 100. The same gap shows up over 3 years (118% against 89.3%).
- **Long term:** ABBV turned $10,000 into $70,300 over the past decade, against $42,100 in the S&P 500. ABBV's 10-year return of 603% puts it ahead of 89% of the stocks worth at least $300 million with that much history. The S&P 500 returned 321%.
- **In a crash:** ABBV fell less than the S&P 500 in three of four sell-offs, but the 2015 China and oil sell-off broke the pattern: it fell 29.8%, more than the S&P 500's 12.8%.
- **Diversification:** Against the S&P 500, ABBV has a correlation of 0.17 over 5 years, less closely than 89% of stocks worth at least $300 million. Next to an index fund it is a real diversifier. Over 10 years, ABBV's beta versus the S&P 500 was 0.54: 92% of the S&P 500's gains in rising months and 57% of its losses in falling ones.
- **Better options**
  - **Popular alternatives:** LLY (Eli Lilly and Company) fell less than ABBV in each recent sell-off and kept up with it over the past decade.
  - **Nearby categories and themes:** MCK (McKesson, health care distribution) earned more for the risk it took than ABBV over the past 5 years, and its worst fall in 10 years was 38.1%, against 45.1% for ABBV.
  - **Whole market:** Nothing in the whole market did better on both counts: none of the 3,633 stocks and funds worth at least $500 million earned more than ABBV with less volatility over the past 5 years.

## How much would $10,000 in ABBV have grown?

This chart tracks a hypothetical $10,000 investment in ABBV over the past 13 years, with dividends reinvested, alongside the same amount in the S&P 500, investments that ended ahead of ABBV over the same span and ABBV's popular alternatives, among those that traded for the entire period.

- $10,000 invested in ABBV at the end of September 2013 would have grown to $97,598 by September 2026, more than the $56,474 it would have become in SPY, an S&P 500 fund.
- Five of the eight other investments on the chart ended ahead of ABBV, and NVDA finished highest, at $6,301,092.

## ABBV at a glance

This section summarizes the key facts about the stock, its returns over periods from one to ten years and the risk it has carried, with dividends reinvested throughout.

- ABBV is trading within 1% of its all-time high.
- ABBV's deepest decline since it began trading in 2012 was 45.1%, from January 2018 to August 2019. It took 16 months from the low to climb back to its old high.
- Over 13 full calendar years, ABBV's best was 2013, when it returned 60.7%, and its worst was 2015, when it lost 6.5%. It lost money in three of those years.

- Type: Stock, Healthcare (Drug Manufacturers - General)
- Trading since: December 10, 2012
- Market value: $511B
- Volatility (5 years): 23.4%; Sharpe ratio: 1.11
- Worst decline ever: −45.1%, from January 26, 2018 to August 15, 2019; back at its high by December 4, 2020

| Period | ABBV total return |
| --- | --- |
| 1 month | +9.9% |
| 3 months | +14.8% |
| 6 months | +43.8% |
| year to date | +29.8% |
| 1 year | +28.3% |
| 3 years | +118% |
| 5 years | +218% |
| 10 years | +603% |

## ABBV against the whole market

Where ABBV ranks among every stock and fund, and what across the market has done better.

### How does ABBV rank among all stocks?

This section ranks ABBV on return, volatility, risk-adjusted return and worst decline against every stock worth at least $300 million with enough history.

- On return for the risk taken (the Sharpe ratio), ABBV ranks in the top 2% of the 2,893 stocks worth at least $300 million.

| Measure | ABBV | Rank |
| --- | --- | --- |
| 1-year return | +28.3% | 1,021 of 3,287 (top 32%) |
| 3-year return | +118% | 779 of 3,017 (top 26%) |
| 5-year return | +218% | 279 of 2,893 (top 10%) |
| 10-year return | +603% | 232 of 2,202 (top 11%) |
| Volatility, 5 years | 23.4% | 229 of 2,893 (top 8%) |
| Sharpe ratio, 5 years | 1.11 | 46 of 2,893 (top 2%) |
| Worst decline, past 10 years | −45.1% | 291 of 2,187 (top 14%) |

### What has beaten ABBV on both return and risk?

Each dot is an investment, placed by how much it earned a year over the past 5 years (higher is better) and how much its price swung, its volatility (further left is calmer).

- None of the 3,633 stocks and funds worth at least $500 million earned more than ABBV over the past 5 years with less volatility: nothing sits in the green region.

### Is there a better investment than ABBV?

The table below lists investments that beat ABBV over the past 5 years on at least one of these measures: a higher annual return with lower volatility, a higher annual return at similar volatility, a similar return with lower volatility, a higher Sharpe ratio with a smaller worst decline, a higher total return in most periods from 3 months to 10 years, or smaller losses in recent market crashes.

- Among ABBV's popular alternatives, LLY fell less than ABBV in each recent sell-off and kept up with it over the past decade.
- Looking beyond its popular alternatives, MCK (health care distribution) earned more for the risk it took than ABBV over the past 5 years, and its worst fall in 10 years was 38.1%, against 45.1% for ABBV.
- Nothing in the whole market did better on both counts: none of the 3,633 stocks and funds worth at least $500 million earned more than ABBV with less volatility over the past 5 years.

## ABBV against its popular alternatives

The investments people most often weigh against ABBV, compared period by period and year by year.

### How do ABBV's risk and return compare with its alternatives?

This map plots each investment's annual return over the past 5 years against its volatility, the size of its typical price swings.

- None of the 20 popular alternatives earned more than ABBV over the past 5 years with smaller price swings, so every higher return on the map came with a bumpier ride.
- 15 of the 20 popular alternatives earned less than ABBV over the past 5 years while swinging more, the weaker corner of the map.
- Over the past 5 years, ABBV returned 26.1% a year, more than the S&P 500's 12.7%, with higher volatility (23.4% against 17.1%).

### Has ABBV consistently beaten its popular alternatives?

This section compares ABBV with the investments people most often weigh against it, checking each one over eight periods from one month to ten years.

- None of the 20 popular alternatives outperformed ABBV in at least 3 of 5 short-term and 2 of 3 long-term timeframes. The closest was LLY.
- LLY earned more for the risk it took than ABBV (a higher Sharpe ratio) and fell less in its worst decline of the past 10 years.
- LLY outperformed ABBV over all three long-term periods but in only one of the five short-term ones, so ABBV has had the better of it lately.

| Investment | 1Y return | 3Y return | 5Y return | 10Y return | Periods ahead of ABBV | Verdict | Sharpe |
| --- | --- | --- | --- | --- | --- | --- | --- |
| ABBV: AbbVie Inc. (this page) | +28.3% | +118% | +218% | +603% |  |  | 1.11 |
| [LLY](https://easycompare.io/research/lly): Eli Lilly and Company | +59.7% | +124% | +451% | +1,807% | 1/5 short-term, 3/3 long-term |  | 1.21 |
| VTRS: Viatris Inc. | +87.1% | +127% | +64.3% | −38.0% | 2/5 short-term, 1/3 long-term |  | 0.47 |
| [AMGN](https://easycompare.io/research/amgn): Amgen Inc. | +48.7% | +72.2% | +145% | +266% | 4/5 short-term, 0/3 long-term |  | 0.85 |
| BIIB: Biogen Inc. | +65.8% | −5.6% | −8.8% | −18.9% | 4/5 short-term, 0/3 long-term |  | 0.11 |
| [MRK](https://easycompare.io/research/mrk): Merck & Co., Inc. | +76.8% | +58.3% | +113% | +241% | 3/5 short-term, 0/3 long-term |  | 0.74 |
| [GILD](https://easycompare.io/research/gild): Gilead Sciences, Inc. | +30.3% | +121% | +180% | +200% | 3/5 short-term, 0/3 long-term |  | 0.95 |
| [TAK](https://easycompare.io/research/tak): Takeda Pharmaceutical Company Limited | +48.2% | +56.1% | +75.1% | +30.4% | 3/5 short-term, 0/3 long-term |  | 0.68 |
| WST: West Pharmaceutical Services, Inc. | +41.9% | +7.8% | −5.0% | +455% | 2/5 short-term, 0/3 long-term |  | 0.19 |
| [IQV](https://easycompare.io/research/iqv): IQVIA Holdings Inc. | +26.3% | +45.3% | +6.5% | +260% | 2/5 short-term, 0/3 long-term |  | 0.21 |
| [REGN](https://easycompare.io/research/regn): Regeneron Pharmaceuticals, Inc. | +40.7% | +0.8% | +44.9% | +120% | 2/5 short-term, 0/3 long-term |  | 0.40 |
| [PFE](https://easycompare.io/research/pfe): Pfizer Inc. | +30.5% | +19.2% | −8.3% | +55.0% | 2/5 short-term, 0/3 long-term |  | 0.06 |
| [TMO](https://easycompare.io/research/tmo): Thermo Fisher Scientific Inc. | +26.8% | +49.5% | +15.1% | +366% | 1/5 short-term, 0/3 long-term |  | 0.24 |
| [JNJ](https://easycompare.io/research/jnj): Johnson & Johnson | +36.9% | +84.6% | +82.1% | +196% | 1/5 short-term, 0/3 long-term |  | 0.76 |
| [BMY](https://easycompare.io/research/bmy): Bristol-Myers Squibb Company | +47.8% | +25.8% | +30.6% | +74.8% | 1/5 short-term, 0/3 long-term |  | 0.34 |
| [AZN](https://easycompare.io/research/azn): AstraZeneca PLC | +1.8% | +38.8% | +52.1% | +257% | 0/5 short-term, 0/3 long-term |  | 0.41 |
| [NVS](https://easycompare.io/research/nvs): Novartis AG | +18.8% | +75.9% | +121% | +226% | 0/5 short-term, 0/3 long-term |  | 0.87 |
| [ABT](https://easycompare.io/research/abt): Abbott Laboratories | −18.7% | +13.0% | −8.0% | +204% | 0/5 short-term, 0/3 long-term |  | 0.04 |
| [NVO](https://easycompare.io/research/nvo): Novo Nordisk A/S | −28.5% | −57.0% | −18.5% | +134% | 0/5 short-term, 0/3 long-term |  | 0.09 |
| [GSK](https://easycompare.io/research/gsk): GSK plc | +18.9% | +60.0% | +57.2% | +95.1% | 0/5 short-term, 0/3 long-term |  | 0.49 |
| [SNY](https://easycompare.io/research/sny): Sanofi | −13.4% | −10.0% | +3.0% | +61.5% | 0/5 short-term, 0/3 long-term |  | 0.15 |

### How did ABBV do year by year?

This table shows each investment's total return in every full calendar year since 2013, along with where ABBV ranked among its popular alternatives each year.

- Ranked against its popular alternatives each year, ABBV finished in the top quarter in six of 13 years and in the bottom quarter in two. In 2025, it ranked 7 of 21.
- ABBV finished ahead of the S&P 500 in eight of its 13 full calendar years.
- Among its popular alternatives, LLY came out ahead of ABBV most often, in ten of the 13 years both traded.

| Year | ABBV | SPY |
| --- | --- | --- |
| 2025 | +33.1% | +17.7% |
| 2024 | +18.9% | +24.9% |
| 2023 | −0.2% | +26.2% |
| 2022 | +24.0% | −18.2% |
| 2021 | +32.4% | +28.7% |
| 2020 | +27.7% | +18.3% |
| 2019 | +1.5% | +31.2% |
| 2018 | −1.0% | −4.6% |
| 2017 | +60.1% | +21.7% |
| 2016 | +9.8% | +12.0% |

## Risk and diversification

How ABBV has fallen, how it held up in crashes beside the S&P 500 and its popular alternatives, and what moves independently of it.

### What were ABBV's worst declines?

A drawdown is the decline from a peak to the lowest point before a new high.

- In all five of ABBV's worst declines, the S&P 500 held up better over the same dates.
- Not every decline was the market's doing: ABBV fell 45.1% from January 2018 to August 2019, while the S&P 500 rose 2.1%.
- The longest climb back to a previous high took 19 months, after ABBV fell 31.6% from July to October 2015.

| Decline | Peak | Low | Back at the high | SPY over the same dates | Market event |
| --- | --- | --- | --- | --- | --- |
| −45.1% | January 26, 2018 | August 15, 2019 | December 4, 2020 | +2.1% | late-2018 sell-off |
| −31.6% | July 28, 2015 | October 22, 2015 | May 2, 2017 | −1.4% | 2015 China and oil sell-off |
| −21.9% | April 8, 2022 | September 30, 2022 | January 10, 2024 | −19.5% | 2022 bear market |
| −20.7% | March 10, 2025 | April 21, 2025 | September 4, 2025 | −8.1% |  |
| −19.8% | December 5, 2014 | February 9, 2015 | June 18, 2015 | −1.1% |  |

### How did ABBV do in stock market crashes?

This section measures how far ABBV, the S&P 500 and each alternative fell from peak to trough during every major market crash since 2000.

- ABBV fell less than the S&P 500 in five of the six crashes it has traded through. The clearest case was the 2022 bear market, when ABBV fell 21.9% and the S&P 500 fell 24.5%.
- Among its popular alternatives, LLY held up best, falling less than ABBV in five of the six crashes they both traded through.
- ABBV began trading after the 2008 financial crisis, but 18 of its popular alternatives lived through it. The mildest fall among them was ABT's 22.3%, against 55.2% for the S&P 500.

| Crash | Dates | ABBV fall | SPY fall |
| --- | --- | --- | --- |
| Dot-com bust | March 10, 2000 to October 9, 2002 | not trading | −47.5% |
| Global financial crisis | October 9, 2007 to March 9, 2009 | not trading | −55.2% |
| Flash crash | May 6, 2010 to May 7, 2010 | not trading | −1.5% |
| Euro debt crisis | July 22, 2011 to October 3, 2011 | not trading | −17.9% |
| China devaluation & oil rout | August 10, 2015 to February 11, 2016 | −29.8% | −12.8% |
| Volmageddon | February 2, 2018 to February 9, 2018 | −5.8% | −6.5% |
| Q4 2018 selloff | September 21, 2018 to December 24, 2018 | −18.1% | −19.3% |
| COVID crash | February 19, 2020 to March 23, 2020 | −32.1% | −33.7% |
| 2022 bear market | January 4, 2022 to October 12, 2022 | −21.9% | −24.5% |
| SVB / regional bank stress | March 8, 2023 to March 13, 2023 | −1.5% | −3.4% |

### How closely does ABBV move with the S&P 500?

Upside capture measures how much of the S&P 500's gains an investment kept in the months the market rose, and downside capture how much of its losses it took in the months the market fell.

- Over the past 10 years, ABBV captured 92% of the S&P 500's gains in rising months and 57% of its losses in falling months, with a beta of 0.54. That is a defensive profile: it gave up some of the market's upside in exchange for smaller losses.
- Only LLY had a higher capture ratio (upside capture divided by downside capture) than ABBV's 1.62, out of 20 popular alternatives with the same record.
- LLY took just 6% of the S&P 500's losses, against 57% for ABBV, while still keeping 101% of its gains.

Measured over the past 10 years of monthly returns against SPY.

| Investment | Upside capture | Downside capture | Beta |
| --- | --- | --- | --- |
| ABBV: AbbVie Inc. (this page) | 92.0% | 57.0% | 0.54 |
| [LLY](https://easycompare.io/research/lly): Eli Lilly and Company | 101% | 6.0% | 0.37 |
| VTRS: Viatris Inc. | 74.0% | 179% | 1.14 |
| [AMGN](https://easycompare.io/research/amgn): Amgen Inc. | 74.0% | 64.0% | 0.54 |
| BIIB: Biogen Inc. | 35.0% | 91.0% | 0.28 |
| [MRK](https://easycompare.io/research/mrk): Merck & Co., Inc. | 64.0% | 46.0% | 0.30 |
| [GILD](https://easycompare.io/research/gild): Gilead Sciences, Inc. | 52.0% | 36.0% | 0.35 |
| [TAK](https://easycompare.io/research/tak): Takeda Pharmaceutical Company Limited | 34.0% | 58.0% | 0.44 |
| WST: West Pharmaceutical Services, Inc. | 107% | 99.0% | 1.08 |
| [IQV](https://easycompare.io/research/iqv): IQVIA Holdings Inc. | 128% | 167% | 1.31 |
| [REGN](https://easycompare.io/research/regn): Regeneron Pharmaceuticals, Inc. | 55.0% | 66.0% | 0.19 |
| [PFE](https://easycompare.io/research/pfe): Pfizer Inc. | 52.0% | 81.0% | 0.54 |
| [TMO](https://easycompare.io/research/tmo): Thermo Fisher Scientific Inc. | 104% | 104% | 0.81 |
| [JNJ](https://easycompare.io/research/jnj): Johnson & Johnson | 64.0% | 53.0% | 0.46 |
| [BMY](https://easycompare.io/research/bmy): Bristol-Myers Squibb Company | 55.0% | 75.0% | 0.41 |
| [AZN](https://easycompare.io/research/azn): AstraZeneca PLC | 60.0% | 39.0% | 0.39 |
| [NVS](https://easycompare.io/research/nvs): Novartis AG | 69.0% | 64.0% | 0.49 |
| [ABT](https://easycompare.io/research/abt): Abbott Laboratories | 76.0% | 79.0% | 0.64 |
| [NVO](https://easycompare.io/research/nvo): Novo Nordisk A/S | 75.0% | 94.0% | 0.60 |
| [GSK](https://easycompare.io/research/gsk): GSK plc | 51.0% | 61.0% | 0.52 |
| [SNY](https://easycompare.io/research/sny): Sanofi | 53.0% | 74.0% | 0.46 |

### What diversifies ABBV?

Correlation measures how closely two investments move together, on a scale from 1 (in lockstep) through 0 (unrelated) to -1 (in opposite directions).

- Moving a fifth of the money in ABBV into DXJ would have cut the portfolio's volatility by 18% over the past 5 years and raised its annual return (+23.8% for ABBV alone, +25.0% for the mix).
- FIX made money in three of the three calendar years in which ABBV lost money.
- Among large ETFs, LVHI, DXJ and EMLP have moved largely independently of ABBV over the past 5 years, with correlations of 0.27 or lower, and each still earned a positive 5-year return.

| Investment | Correlation with ABBV | 5Y return | Volatility | Sharpe | Rose in ABBV's 3 down years |
| --- | --- | --- | --- | --- | --- |
| LVHI: Franklin International Low Volatility High Dividend Index ETF | 0.27 | +119% | 11.1% | 1.48 | 1 of 3 |
| DXJ: WisdomTree Japan Hedged Equity Fund | 0.11 | +225% | 19.1% | 1.34 | 2 of 3 |
| EMLP: First Trust North American Energy Infrastructure Fund | 0.19 | +101% | 14.5% | 1.04 | 1 of 3 |
| HDV: iShares Core High Dividend ETF | 0.46 | +83.3% | 13.0% | 1.00 | 1 of 3 |
| [SMH](https://easycompare.io/research/smh): VanEck Semiconductor ETF | 0.05 | +323% | 36.9% | 0.97 | 1 of 3 |
| DBEF: Xtrackers MSCI EAFE Hedged Equity ETF | 0.25 | +85.0% | 13.8% | 0.96 | 2 of 3 |
| [GLD](https://easycompare.io/research/gld): SPDR Gold Shares | 0.14 | +126% | 18.9% | 0.96 | 1 of 3 |
| SPMO: Invesco S&P 500 Momentum ETF | 0.23 | +136% | 20.8% | 0.93 | 1 of 3 |

## Common questions

### What was ABBV's worst drawdown?

ABBV's deepest decline since it began trading in 2012 was 45.1%, from January 2018 to August 2019. It took 16 months from the low to climb back to its old high. Because ABBV launched in December 2012, that record does not include the dot-com bust, the 2008 financial crisis or two other sell-offs.

### What were ABBV's best and worst years?

Over 13 full calendar years, ABBV's best year was 2013, when it returned 60.7%. Its worst was 2015, with a return of -6.5%.

### Is there a better investment than ABBV?

Among ABBV's popular alternatives, LLY fell less than ABBV in each recent sell-off and kept up with it over the past decade. Looking beyond its popular alternatives, MCK (health care distribution) earned more for the risk it took than ABBV over the past 5 years, and its worst fall in 10 years was 38.1%, against 45.1% for ABBV.

### Is ABBV more volatile than the S&P 500?

Yes. ABBV's volatility over the past 5 years was 23.4%, 1.4 times the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, ABBV's return lands within 23.4% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump.

### What is ABBV's Sharpe ratio?

ABBV's Sharpe ratio over the past 5 years was 1.11, against 0.79 for the S&P 500, so ABBV earned more for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings.

### How correlated is ABBV with the S&P 500?

Over the past 5 years, ABBV's monthly returns had a correlation of 0.17 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They are only loosely linked, which makes it a real diversifier next to an index fund. In the table, the correlation column measures each option against ABBV instead: the lower it is, the more that option would diversify a ABBV holding.

### What are the best alternatives to ABBV?

None of the 20 popular alternatives we compared outperformed ABBV in at least 3 of 5 short-term and 2 of 3 long-term timeframes, which says more about ABBV's strength than about its alternatives.

### Did ABBV outperform the S&P 500?

ABBV finished ahead of the S&P 500 (SPY) in eight of 13 full calendar years. In 2025, it returned +33.1%, against +17.7% for the index.

### How did ABBV do in stock market crashes?

ABBV fell less than the S&P 500 (SPY) in five of the six major crashes it has traded through, and further in one. The clearest case was the 2022 bear market, when ABBV fell 21.9% and the S&P 500 fell 24.5%.

### What diversifies ABBV?

These had a low correlation with ABBV over the past 5 years and still earned a positive 5-year return: among large ETFs, LVHI (correlation 0.27), DXJ (correlation 0.11) and EMLP (correlation 0.19); among large stocks, CAH (correlation 0.07), CLS (correlation -0.02) and FIX (correlation -0.02). A correlation near zero means the two have moved largely independently.

## More research

- [Eli Lilly and Company (LLY) Performance, Alternatives and Market Rank](https://easycompare.io/research/lly)
- [Amgen (AMGN) Performance, Alternatives and Market Rank](https://easycompare.io/research/amgn)
- [Merck & Co., Inc. (MRK) Performance, Alternatives and Market Rank](https://easycompare.io/research/mrk)
- [Gilead Sciences (GILD) Performance, Alternatives and Market Rank](https://easycompare.io/research/gild)
- [Takeda Pharmaceutical (TAK) Performance, Alternatives and Market Rank](https://easycompare.io/research/tak)
- [IQVIA (IQV) Performance, Alternatives and Market Rank](https://easycompare.io/research/iqv)
- [Regeneron Pharmaceuticals (REGN) Performance, Alternatives and Market Rank](https://easycompare.io/research/regn)
- [Pfizer (PFE) Performance, Alternatives and Market Rank](https://easycompare.io/research/pfe)
- [Thermo Fisher Scientific (TMO) Performance, Alternatives and Market Rank](https://easycompare.io/research/tmo)
- [Johnson & Johnson (JNJ) Performance, Alternatives and Market Rank](https://easycompare.io/research/jnj)
- [Bristol-Myers Squibb (BMY) Performance, Alternatives and Market Rank](https://easycompare.io/research/bmy)
- [AstraZeneca (AZN) Performance, Alternatives and Market Rank](https://easycompare.io/research/azn)

## Explore further

- Full page with charts: https://easycompare.io/research/abbv
- All research pages: https://easycompare.io/llms.txt
- Compare the entire market against ABBV live: https://betterthanspy.com/?b=ABBV&utm_source=easycompare&utm_medium=research